73908
document
Comparison of the efficacy and safety of esmolol , a short-acting beta blocker , with placebo in the treatment of supraventricular tachyarrhythmias . The Esmolol vs Placebo Multicenter Study Group . The efficacy and safety of esmolol , a short-acting intravenous beta-adrenergic-blocking agent , and placebo were compared in patients with supraventricular tachyarrhythmias ( heart rate greater than 120 bpm ) in a multicenter , double-blind , partial-crossover study . Seventy-one patients were randomized to receive either esmolol ( n = 36 ) or placebo ( n = 35 ) as initial treatment . Therapeutic failures were crossed over to the other study medication . Therapeutic response was defined as greater than or equal to 20 % reduction in heart rate , heart rate less than 100 bpm , or conversion to normal sinus rhythm . The therapeutic response to esmolol during the initial treatment period ( 72 % ) was similar to that obtained when esmolol was given as a second agent . The average esmolol dosage producing a therapeutic response was 97.5 micrograms/kg/min . Four patients ( 6 % ) converted to normal sinus rhythm during esmolol infusion . In the majority of patients ( 80 % ) , therapeutic response was lost within 30 minutes following discontinuation of esmolol infusion , a finding indicative of rapid reversal of beta-adrenoceptor blockade . The most prevalent adverse effect during esmolol infusion was hypotension which occurred in eight patients ( 12 % ) . Hypotension and associated symptoms resolved within 30 minutes after discontinuation of esmolol infusion , which is consistent with the short duration of action of esmolol ( elimination half-life of 9.2 minutes ) .
73909
Intervention_Pharmacological
esmolol
73910
Intervention_Control
placebo
73911
Intervention_Pharmacological
Esmolol
73912
Intervention_Pharmacological
Placebo
73913
Intervention_Pharmacological
esmolol
73914
Intervention_Control
placebo
73915
Intervention_Pharmacological
esmolol
73916
Intervention_Control
placebo
73917
Intervention_Pharmacological
esmolol
73918
Intervention_Pharmacological
esmolol
73919
Intervention_Pharmacological
esmolol
73920
Intervention_Pharmacological
esmolol
73921
Intervention_Pharmacological
esmolol
73922
Outcome_Other
efficacy
73923
Outcome_Other
safety
73924
Outcome_Other
efficacy
73925
Outcome_Other
safety
73926
Outcome_Physical
Therapeutic response
73927
Outcome_Physical
heart rate
73928
Outcome_Physical
heart rate less than 100 bpm
73929
Outcome_Physical
conversion to normal sinus rhythm
73930
Outcome_Other
The therapeutic response
73931
Outcome_Physical
normal sinus rhythm
73932
Outcome_Other
therapeutic response
73933
Outcome_Adverse-effects
adverse effect
73934
Outcome_Adverse-effects
hypotension
73935
Outcome_Adverse-effects
Hypotension and associated symptoms
73936
Participant_Condition
supraventricular tachyarrhythmias .
73937
Participant_Condition
supraventricular tachyarrhythmias
73938
Participant_Sample-size
Seventy-one